ResMed Inc (BSP:R1MD34)
R$ 368.7 0.14 (0.04%) Market Cap: 216.49 Bil Enterprise Value: 218.91 Bil PE Ratio: 32.69 PB Ratio: 6.97 GF Score: 87/100

Resmed Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 19, 2019 / 10:25AM GMT
Lyanne Harrison
BofA Merrill Lynch, Research Division - VP

Good morning, gentlemen, and welcome to our conversation with ResMed. I am Lyanne Harrison and I cover healthcare in Australia. And today, I have with me Robert Douglas; COO of ResMed; David Pendarvis, CAO; and Amy Wakeham, Head of Investor Relations.

So Rob, Dave, Amy, thank you for joining us and making your way to London.

David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary

Thanks very much.

Robert A. Douglas
ResMed Inc. - President & COO

Thanks, Lyanne.

Lyanne Harrison
BofA Merrill Lynch, Research Division - VP

So for those of you who are not familiar with the ResMed story, I might get Rob to start with the presentation and an overview on ResMed.

Robert A. Douglas
ResMed Inc. - President & COO

Sure. Thanks, Lyanne. So we're just going to talk a little bit about ResMed's overall strategy in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot